In this FDA staff article, “Cancer risk associated with lorcaserin — The FDA’s review of the CAMELLIA-TIMI 61 trial”, which was published by the New England Journal of Medicine (NEJM), the early 2020 FDA Belviq recall decision was explained. Essentially, this FDA action after a careful analysis of Belviq safety data that revealed excess … [Read more...]
Private Settlement Reached in Mesothelioma Case
A private settlement was reached in a mass litigation asbestos case [on July 28, 2020] in Ohio County [(West Virginia)] Circuit Court, meaning a trial set to take place at The Highlands Event Center next week won’t be necessary. Both Ohio County Clerk of Courts Brenda Miller and court employees for Judge Ronald Wilson said details of the … [Read more...]
After Drug Recall Belviq Lawsuits Alleging Failure To Warn About Cancer
Following the Belviq recall in February 2020 some of those patients on Belviq developing cancer filed Belviq lawsuits alleging a failure to warn about the risk of cancer associated with Belviq. We are investigating possible Belviq lawsuits that involve patients on Belviq developing cancer. At the present time, our focus for these Belviq lawsuits … [Read more...]
EPA finds asbestos poses cancer risks for workers, reigniting calls for ban
The Environmental Protection Agency (EPA) has determined that [ asbestos dust ] poses an unreasonable risk of [ lung cancer and mesothelioma ] to both workers and consumers who inhale it, ramping up pressure on the agency to ban the substance. In a draft risk assessment published this week, the EPA said that workers who inhale [ asbestos dust ] … [Read more...]
Belviq Recall Due To Certain Cancers: Pancreatic, Colon, Rectal, And Lung
The diet drug Belviq is being withdrawn from the US market because a Belviq safety clinical trial shows an increased occurrence of cancer cases. This February 2020 Belviq FDA Drug Safety Communication announced the Belviq recall, “FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market”, and noted that … [Read more...]
Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: therapeutic implications
Introduction: We compared the secretome of metastatic (non-small cell lung cancer (NSCLC)) and primary (mesothelioma) malignant pleural effusions, benign effusions and the published plasma profile of patients receiving chimeric antigen receptor T cells (CAR-T), to determine factors unique to neoplasia in pleural effusion (PE) and those accompanying … [Read more...]
A Most Reckless Proposal — A Plan to Continue Asbestos Use in the United States
Each year, nearly 40,000 Americans die often painful, protracted deaths from diseases caused by asbestos. These deaths occur in firefighters, police officers, construction workers, miners, military veterans, shipyard workers, and maintenance workers whose exposures to asbestos are primarily occupational. Death also occurs in partners and children … [Read more...]
Costs related to asbestos exposure much higher than original estimates
The annual cost of newly diagnosed mesothelioma and lung cancer due to work-related asbestos exposure is significantly higher than first thought, according to a study by the Institute for Work & Health. The original tab was $1.9 billion, but a review of figures now puts that cost at $2.35 billion, according to research by senior scientist … [Read more...]
Chest ultrasonography in health surveillance of asbestos-related lung diseases
Exposure to asbestos fibers can lead to different lung diseases, such as pleural thickening and effusion, asbestosis, mesothelioma, and lung cancer. These diseases are expected to peak in the next few years. The aim of the study was to validate ultrasonography (US) as a diagnostic tool in the management of lung diseases in subjects with a history … [Read more...]